版本:
中国

BRIEF-Mirna Therapeutics halts phase 1 clinical study of MRX34

Sept 20 Mirna Therapeutics Inc :

* Will discuss with advisors, as well as fda regarding possible future development of MRX34

* Company voluntarily halted enrollment and dosing in clinical study following multiple immune-related severe adverse events

* Will not be initiating a translational medicine study of MRX34 in melanoma patients, planned to begin later this year Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐